Madrigal Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Madrigal Pharmaceuticals

MDGL 474.98

+6.7%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lynn	6/13/2018 7:50:35 PM
	of 138

Madrigal Pharma explores sale: Bloomberg Deals June 13, 2018 / 12:11 PM / Updated 7 hours ago Reuters Staff (Reuters) - Madrigal Pharmaceuticals Inc ( MDGL.O) is exploring a sale, Bloomberg reported on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH. The company is exploring a sale after receiving takeover interest from drugmakers eying treatments for NASH, the report said. Madrigal Pharmaceuticals Inc313.24 MDGL.OConsolidated Issue listed on NASDAQ Capital Market +30.53(+10.80%) MDGL.O The deliberations were at an early stage and the company was working with investment bank Centerview Partners Holdings on the potential sale, the Bloomberg report said. U.S.-based Madrigal saw its stock more than double since it reported the data. Shares of the company, which had a market valuation of $4.31 billion to Tuesday’s close, rose 6.2 percent to $299.09 on Wednesday. The company did not immediately respond to a request for comment. Often dubbed the “silent disease” because it frequently goes undiagnosed, NASH has no approved treatment and the lucrative size of the market has led large drugmakers to hunt for deals with smaller companies with promising treatments for the disease. reuters.com Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel Our Standards: The Thomson Reuters Trust Principles. reuters.com I would prefer getting shares than cash if/when MDGR is sold.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next